Quest Diagnostics Inc vs NEOS S&P 500 High Income ETF — how do they compare? Quest Diagnostics Inc trades at $237.5 (market cap $26.21B), while NEOS S&P 500 High Income ETF trades at $54.25. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while NEOS S&P 500 High Income ETF pays none. Which is the better fit depends on your goals.
| DGX | SPYI | |
|---|---|---|
Market Cap | $26.21B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $238.50 | $54.19 |
52-Week Low | $173.49 | $47.98 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | — |
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →